Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from CSL ( (AU:CSL) ) is now available.
CSL Limited has provided an updated notification to the ASX on the progress of its on-market share buy-back program for its ordinary fully paid shares. The company reported that a cumulative 5,896,686 shares had been repurchased prior to the latest trading day, with an additional 101,810 shares bought back on the previous day.
The latest daily disclosure, dated 24 April 2026, reflects CSL’s ongoing execution of a buy-back first announced in August 2025. The continued on-market repurchases indicate the company’s active capital management strategy, which can support earnings per share and signal confidence in its valuation to investors.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$212.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited is a global biotechnology company best known for developing and manufacturing vaccines, plasma-derived therapies and other innovative biopharmaceutical products. The group serves patients, healthcare providers and governments worldwide, with a focus on immunology, hematology, respiratory, and rare and serious disease markets.
Average Trading Volume: 1,365,674
Technical Sentiment Signal: Sell
Current Market Cap: A$66.49B
Learn more about CSL stock on TipRanks’ Stock Analysis page.